title: Evaluation of orally administered robenacoxib versus ketoprofen for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats.
abstract: OBJECTIVE
  To evaluate the efficacy and tolerability of oral administration of robenacoxib for treatment of acute pain and inflammation associated with musculoskeletal disorders in cats.
  
  
  METHODS
  155 cats requiring relief of signs of pain and inflammation associated with acute musculoskeletal disorders.
  
  
  METHODS
  The study was a multicenter, prospective, randomized, masked, noninferiority field trial. Cats were allocated randomly to 1 of 3 treatment groups: group 1 (1.0 to 2.4 mg of robenacoxib/kg, q 24 h), group 2 (1.0 to 2.4 mg of robenacoxib/kg, q 12 h [daily dosage, 2.0 to 4.8 mg/kg]), and group 3 (ketoprofen [mean dosage, 1 mg/kg, q 24 h]). All cats were administered tablets PO for 5 or 6 days. The primary efficacy endpoint was the investigator global assessment score, which was the sum of scores of signs of pain, inflammation, and mobility assessed in a masked manner by veterinary investigators at baseline, day 2, and day 4 or 5. Cat owners monitored in a nonmasked manner secondary responses by observation of cats' activity, behavior, appetite, and interactions. Safety was assessed by monitoring adverse events, clinical signs, and hematologic and plasma biochemical variables (before and after treatment).
  
  
  RESULTS
  No significant differences were detected among the 3 treatment groups for any primary or secondary efficacy endpoints or for tolerability variables. Robenacoxib tablets administered once daily were significantly more palatable than ketoprofen tablets.
  
  
  CONCLUSIONS
  Robenacoxib tablets administered once daily had noninferior efficacy and tolerability, and superior palatability, compared with the active control drug, ketoprofen, for the treatment of signs of acute pain and inflammation associated with musculoskeletal disorders in cats.
authors.affiliation: Novartis Centre de Recherche Santé Animale SA, CH-1566 StAubin FR, Switzerland.
authors.forename: Jerome M
authors.initials: JM
authors.lastname: Giraudel
authors.forename: Philippe
authors.initials: P
authors.lastname: Gruet
authors.forename: Debbie G
authors.initials: DG
authors.lastname: Alexander
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Seewald
authors.forename: Jonathan N
authors.initials: JN
authors.lastname: King
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000469:Alkaline Phosphatase / Q000097:blood; D000818:Animals; D001066:Appetite / Q000187:drug effects; D001219:Aspartate Aminotransferases / Q000097:blood; D001522:Behavior, Animal / Q000187:drug effects; D002371:Cat Diseases / Q000188:drug therapy*; D002415:Cats; D052246:Cyclooxygenase 2 Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D007249:Inflammation / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D007660:Ketoprofen / Q000627:therapeutic use*; D009140:Musculoskeletal Diseases / Q000188:drug therapy / Q000662:veterinary*; D010146:Pain / Q000188:drug therapy / Q000209:etiology / Q000662:veterinary*; D011451:Prostaglandin-Endoperoxide Synthases / Q000097:blood; D012044:Regression Analysis
chemical_list: D052246:Cyclooxygenase 2 Inhibitors; D007660:Ketoprofen; D011451:Prostaglandin-Endoperoxide Synthases; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000469:Alkaline Phosphatase